The Lung Cancer Channel on VJOncology is supported by Janssen Oncology (a pharmaceutical company of Johnson & Johnson), Takeda and AstraZeneca. These supporters have no influence over the production of the content.
The introduction of immunotherapy into the treatment paradigm for lung cancer has improved patient outcomes in recent times. These include checkpoint inhibitors, such as atezolizumab, nivolumab and pembrolizumab for patients with metastatic NSCLC, as well as monoclonal antibodies such as bevacizumab, ramucirumab and durvalumab. Further research into potential vaccinations, as well as other ways of manipulating the immune system, for lung cancer is ongoing and may raise the exciting prospect of cure.
As with any new therapy, there are always new challenges introduced for managing treatment regimens as well as their potential side effects. The introduction of immunotherapies has evolved the role of oncology nurses and other members of the MDT to deliver safe and effective treatments to patients.View overview page